Three-Day Topotecan Schedule in Heavily Pretreated Recurrent Ovarian Cancer Patients. Issue 3 (1st March 2009)

• Record Type: Journal Article
• Authors: Calcagno, Marco; Bellati, Filippo; Palaia, Innocenza; Plotti, Francesco; Basile, Stefano; Pastore, Maria; Sansone, Milena; Arrivi, Cristiana; Angioli, Roberto; Panici, Pierluigi Benedetti
• Is Part Of: International journal of gynecological cancer. Volume 19:Issue 3(2009)
• Page Start: 455
• Page End: 459
• Publication Date: 2009-03-01
• Subjects: Recurrent ovarian cancer -- Salvage chemotherapy -- Topotecan -- 3-day schedule; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1111/IGC.0b013e3181a1a7d2
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Objective: To evaluate the clinical benefit of a 3-day topotecan schedule in heavily pretreated recurrent ovarian cancer patients scheduled for palliative treatment. Methods: Eligibility criteria were 2 or more prior chemotherapy regimens, Eastern Cooperative Oncology Group performance status of 2 or less; adequate organ function, assessable disease by serum CA-125 measurement before each cycle; and 1 or more cycle of topotecan (1.5 mg/m 2 per day) on 3 consecutive days of a 28-day treatment cycle. Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria version 3. Tumor response, stable disease, and progression were evaluated on the basis of CA-125 levels. Results: A total of 68 patients were considered eligible for the study. Median age was 58 years (range, 40-77 years), and the median number of prior chemotherapy regimens was 2 (range, 2-6). A total of 272 cycles of topotecan were administered, with a median of 4 cycles per patient (range, 1-8). No treatment delays or dose reduction was recorded. Major toxicities were grade 3/4 (18%) neutropenia, neutropenic fever (6%), grade 4 thrombocytopenia (3%), requirements for blood (5%), and platelet transfusions (3%). Thirty-five (54%) of the 64 evaluable patients showed a clinical benefit. Of these, 11 patients (17%) had a partial response, and 24 (37%) had stable disease with a median time to progression of 7.5 months (range, 6-10 months) and 4 months (range, 2-6 months), respectively. Conclusion: More than half of heavily pretreated ovarian cancer patients may benefit from 3-day topotecan.